Consensus G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
4.19 ^USD	+2.20%		+2.70%	+37.38%

Feb. 28	G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 28	Wedbush Lifts G1 Therapeutics' PT to $5 From $4, Adjusts Financing, Revenue Expectations; Keeps Outperform Rating	MT

Evolution of the average Target Price on G1 Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

378f79dafd88d23ca75139f.Nnt0GghLWF1r_OnVGfhRSokP8Z1FWFBUCnvaz5zyJqE.VyEmdDE4HBYal9mxYaICONx5kNFwFhIdPQLjq-uKEJFlEkF5TQZtCymSsA~10780b391828448d0d493d226bca7a6b

Analyst Recommendations on G1 Therapeutics, Inc.

Wedbush Lifts G1 Therapeutics' PT to $5 From $4, Adjusts Financing, Revenue Expectations; Keeps Outperform Rating	Feb. 28	MT
Needham Adjusts G1 Therapeutics Price Target to $12 From $14, Maintains Buy Rating	Feb. 13	MT
Wedbush Adjusts G1 Therapeutics' PT to $4 From $5, Keeps Outperform Rating	Feb. 13	MT
JPMorgan Downgrades G1 Therapeutics to Underweight From Neutral	23-10-06	MT
Raymond James Adjusts Price Target on G1 Therapeutics to $8 From $24, Maintains Outperform Rating	23-05-04	MT
Needham Cuts Price Target on G1 Therapeutics to $18 From $31, Maintains Buy Rating	23-02-14	MT
HC Wainwright Lowers Price Target on G1 Therapeutics to $11 From $34, Maintains Buy Rating	23-02-14	MT
EF Hutton Adjusts Price Target on G1 Therapeutics to $19 From $35, Maintains Buy Rating	23-02-13	MT
JPMorgan Upgrades G1 Therapeutics to Neutral From Underweight, Adjusts Price Target to $10 From $7	23-01-30	MT
EF Hutton Initiates G1 Therapeutics at Buy With $35 Price Target	23-01-05	MT
G1 Therapeutics Says Phase 2 Trial Shows Objective Response Rate of 40% in Patients With Bladder Cancer	23-01-04	MT
Needham Adjusts Price Target on G1 Therapeutics to $31 From $32, Maintains Buy Rating	23-01-03	MT
HC Wainwright Adjusts G1 Therapeutics Price Target to $57 From $67, Maintains Buy Rating	22-11-02	MT
Wedbush Lifts Price Target on G1 Therapeutics to $25 From $20, Citing Trilaciclib Potential, Keeps Outperform Rating	22-09-16	MT
Needham Adjusts Price Target on G1 Therapeutics to $32 From $42, Reiterates Buy Rating	22-08-04	MT
Needham Adjusts G1 Therapeutics' Price Target to $42 from $44, Keeps Buy Rating	22-05-05	MT
Wedbush Cuts G1 Therapeutics' Price Target to $20 From $24, Citing Cost of Capital; Outperform Rating Kept	22-05-05	MT
Raymond James Adjusts Price Target on G1 Therapeutics to $24 from $41, Keeps Outperform Rating	21-11-04	MT
HC Wainwright Adjusts G1 Therapeutics' Price Target to $71 from $78, Keeps Buy Rating	21-11-04	MT
JP Morgan Downgrades G1 Therapeutics to Underweight Rating From Neutral, Adjusts Price Target to $19 From $20	21-11-04	MT
G1 THERAPEUTICS : Wedbush Adjusts Price Target for G1 Therapeutics to $24 From $38 Ahead of Q3 Results, Maintains Outperform Rating	21-10-14	MT
G1 THERAPEUTICS : JPMorgan Downgrades G1 Therapeutics to Neutral From Overweight, Cuts Price Target to $20 From $24	21-09-30	MT
G1 THERAPEUTICS : Roth Capital Adjusts Price Target on G1 Therapeutics to $56 From $57, Maintains Buy Rating	21-09-01	MT
G1 THERAPEUTICS : Wedbush Adjusts Price Target on G1 Therapeutics to $38 From $59; Outperform Rating Kept	21-08-05	MT
G1 THERAPEUTICS : Needham Adjusts Price Target on G1 Therapeutics to $68 From $74, Maintains Buy Rating	21-02-25	MT